Clinical trials: Oral Malignancy
Lung Cancer, Non-small Cell Lung Cancer
Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial
The purpose of this study is to assess whether treatment with the study drug tetrahydrouridine-decitabine (THU-Dec) in combination with nivolumab is more effective than treatment with nivolumab alone in patients with NSCLC.
- Trial name
- PRECISE (NCT02664181)
- Testing
- Nivolumab, oral decitabine, Tetrahydrouridine
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive…
- Trial name
- NCT00428714
- Testing
- enzastaurin
- Where
- 11 sites in United States
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
MSC2015103B in Solid Tumors
The main purpose of this study is to test the experimental drug, MSC2015103B at different dose levels and on different treatment schedules, to see whether it is safe and can be tolerated when given to subjects once a day one day…
- Trial name
- NCT01453387
- Testing
- MSC2015103B
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- EMD Serono
Advanced or Inoperable Gastric Cancer
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms.
- Trial name
- NCT03427814
- Testing
- Pamiparib
- Where
- 65 sites in United States, Australia and 14 more
- Volunteers
- 136 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma
Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC
This study will evaluate the role of everolimus in combination with local Transcatheter Arterial Chemoembolization (TACE) procedure in patients with localized unresectable Hepatocellular Carcinoma (HCC).
- Trial name
- TRACER (NCT01379521)
- Testing
- everolimus
- Where
- 5 sites in Hong Kong, Taiwan and 1 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Prostate
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
This 4-year study will compare how safe and effective an oral investigational medicine is (compared to placebo) in preventing the development of prostate cancer in men that are defined by the study entrance criteria as being at…
- Trial name
- REDUCE (NCT00056407)
- Testing
- Dutasteride
- Where
- 932 sites in United States, Argentina and 40 more
- Volunteers
- 8,231 people
- Sponsor
- GlaxoSmithKline
Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
This phase II trial is to see if combining bevacizumab with low-dose cyclophosphamide works in treating patients with ovarian epithelial or primary peritoneal cancer that has come back or spread to other parts of the body.
- Conditions
- Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma, Stage IV Ovarian Cancer
- Trial name
- NCT00072566
- Testing
- Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, T-Cell
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene.
- Trial name
- NCT03703375
- Testing
- Azacitidine, Romidepsin, Gemcitabine
- Where
- 12 sites in Japan
- Volunteers
- 93 people
- Sponsor
- Celgene
Head and Neck Cancer
Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00544414
- Testing
- cisplatin, docetaxel, fluorouracil
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Advanced Solid Tumors
Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Pamiparib in Participants With Advanced Cancer
This is an open-label study, in participants with advanced and/or metastatic solid tumors, which consists of 2 parts: a research phase (inpatient) and a treatment phase.
- Trial name
- NCT03991494
- Testing
- [14C]-pamiparib
- Where
- 2 sites in United Kingdom
- Volunteers
- 4 people
- Sponsor
- BeiGene
Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk
The investigators plan to prospectively study breast tissue changes after a short course of Tamoxifen (Tam).
- Conditions
- Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia, Breast Carcinoma
- Trial name
- NCT04570956
- Testing
- Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 4 mg/each breast/day, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Non Small Cell Lung Cancer
Ponatinib in Advanced NSCLC w/ RET Translocations
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01813734
- Testing
- Ponatinib
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Cancer, Fallopian Tube Cancer
A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
Participants with Ovarian, Fallopian Tube, or Peritoneal Cancer that has recurred within 12 months of prior treatment that includes Platinum Chemotherapy are invited to take part in this study.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT02661815
- Testing
- Paclitaxel, Ricolinostat, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Glioma
Study of Capecitabine to Treat Recurrent High Grade Gliomas
The purpose of this study is to determine if capecitabine is effective in the treatment of high grade gliomas that have returned after completing treatment.
- Trial name
- NCT00717197
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Florida
Head and Neck Cancer
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It may also stop the growth of tumor cells by blocking blood flow to the tumor.
- Trial name
- NCT00425750
- Testing
- bortezomib, docetaxel, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colorectal Cancer
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed…
- Trial name
- NCT02295774
- Testing
- Methylene Blue MMX tablets
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cosmo Technologies Ltd
Multiple Myeloma
Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma
Note: The study data was transferred to zr pharma\& following the divestment of panobinostat to pharma\&. Prior to study completion under the sponsorship of Secura Bio, the study was initiated and conducted in part under the…
- Trial name
- PANORAMA_3 (NCT02654990)
- Testing
- Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
- Where
- 80 sites in United States, Australia and 20 more
- Volunteers
- 248 people
- Sponsor
- pharmaand GmbH
Ovarian Neoplasms
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive…
- Trial name
- ICEBERG 3 (NCT00628251)
- Testing
- AZD2281, Liposomal Doxorubicin
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 97 people
- Sponsor
- AstraZeneca
Mucositis
Low-Level Laser Therapy for Prevention of Oral Mucositis
The overall purpose of this study is to examine the efficacy of prophylactic low-level laser therapy (LLLT) to reduce the incidence of oral mucositis and adverse events in patients receiving combined modality therapy consisting…
- Trial name
- NCT02723604
- Testing
- Low Level Laser Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute